These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7036 related articles for article (PubMed ID: 25207371)
1. Therapy of metastatic malignant melanoma: on the way to individualized disease control. Vogt T Adv Exp Med Biol; 2014; 810():272-81. PubMed ID: 25207371 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Lim SY; Menzies AM; Rizos H Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695 [TBL] [Abstract][Full Text] [Related]
9. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Swe T; Kim KB Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239 [TBL] [Abstract][Full Text] [Related]
10. A new standard of care for metastatic melanoma? Sharma SP Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559 [No Abstract] [Full Text] [Related]
11. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Menzies AM; Long GV Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385 [TBL] [Abstract][Full Text] [Related]
12. BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT; McArthur G Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085 [TBL] [Abstract][Full Text] [Related]
13. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies. McKibbin T Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296 [TBL] [Abstract][Full Text] [Related]
14. [Understanding current therapies in metastatic melanoma]. Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962 [TBL] [Abstract][Full Text] [Related]
15. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Miller DM; Flaherty KT; Tsao H Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Chen G; Davies MA Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945 [TBL] [Abstract][Full Text] [Related]
19. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Dummer R; Flaherty KT Curr Opin Oncol; 2012 Mar; 24(2):150-4. PubMed ID: 22316627 [TBL] [Abstract][Full Text] [Related]
20. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H Front Immunol; 2019; 10():990. PubMed ID: 31134073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]